CytomX Therapeutics, Inc. (CTMX) Stock Price

CTMXStock

$2.28−30.49%52W

Market Cap$496.81M

P/E23.50x

PEG Ratio—

Div yield—

Beta2.27

CTMX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-59.69%

Price vs S&P 500 (4W)-16.07%

VGM Score26.88

P/E Ratio (Annual)23.50x

Book Value / Share (Quarterly)$1.39

P/TBV (Annual)7.32x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.72%

Cash Flow / Share (Quarterly)$-0.38

Price vs S&P 500 (YTD)-58.41%

Net Profit Margin (TTM)-435.21%

EPS (TTM)$-0.44

10-Day Avg Trading Volume3.24M

EPS Excl Extra (TTM)$-0.44

Revenue Growth (5Y)-5.37%

EPS (Annual)$-0.13

ROI (Annual)-17.54%

Net Profit Margin (5Y Avg)-99.53%

Cash / Share (Quarterly)$1.52

P/E Basic Excl Extra (TTM)26.73x

Revenue Growth QoQ (YoY)-92.40%

P/E Normalized (Annual)23.50x

ROA (Last FY)-11.46%

Revenue Growth TTM (YoY)-87.03%

EBITD / Share (TTM)$-0.47

ROE (5Y Avg)-81.98%

Operating Margin (TTM)-476.19%

Cash Flow / Share (Annual)$-0.45

P/B Ratio1.64x

P/B Ratio (Quarterly)2.70x

Net Income / Employee (Annual)$-251,700

EV / Revenue (TTM)26.20x

Net Interest Coverage (TTM)-87.50x

ROA (TTM)-30.33%

EV / EBITDA (TTM)19.67x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)9.25x

3-Month Avg Trading Volume3.93M

52-Week Price Return-30.49%

P/E Incl Extra (TTM)26.73x

Revenue / Employee (TTM)$265,200

Tangible BV / Share (Quarterly)$1.38

P/S Ratio (Annual)6.52x

Asset Turnover (Annual)0.50x

52-Week High$8.21

Operating Margin (5Y Avg)-103.81%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-37.46%

Tangible BV CAGR (5Y)5.15%

26-Week Price Return-49.78%

Quick Ratio (Annual)2.98x

13-Week Price Return-37.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.36x

Enterprise Value$479.59M

Revenue / Share Growth (5Y)-23.99%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-23.01%

Revenue / Employee (Annual)$1,104,400

Pretax Margin (Annual)-22.48%

Cash / Share (Annual)$0.81

3-Month Return Std Dev62.09%

Net Income / Employee (TTM)$-1,154,400

ROE (Last FY)-17.54%

Net Interest Coverage (Annual)-47.58x

EPS Basic Excl Extra (Annual)$-0.13

P/FCF (TTM)53.42x

Receivables Turnover (TTM)0.93x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.44

Receivables Turnover (Annual)29.79x

ROI (TTM)-38.46%

P/S Ratio (TTM)27.15x

Pretax Margin (5Y Avg)-98.67%

Revenue / Share (Annual)$0.55

Tangible BV / Share (Annual)$0.58

Price vs S&P 500 (52W)-46.02%

P/E Ratio (TTM)26.73x

EPS Growth TTM (YoY)-93.03%

Year-to-Date Return-46.48%

5-Day Price Return-5.79%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-11.50%

Net Profit Margin (Annual)-22.79%

Month-to-Date Return-16.18%

Cash Flow / Share (TTM)$-0.39

EBITD / Share (Annual)$-0.15

Operating Margin (Annual)-29.35%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-81.98%

P/E Excl Extra (TTM)26.73x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.44

P/TBV (Quarterly)2.71x

P/B Ratio (Annual)7.29x

Pretax Margin (TTM)-433.95%

Book Value / Share (Annual)$0.58

Price vs S&P 500 (13W)-39.70%

Beta2.27x

P/FCF (Annual)165.60x

Revenue / Share (TTM)$0.08

ROE (TTM)-38.46%

52-Week Low$2.20

vGradeD

gGradeF

mGradeD

vgmGradeD

CTMX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.10	-$0.09	+10.98%(+$0.01)
Q1 2026	May 7, 2026	-$0.11	-$0.10	+13.04%(+$0.01)
Q4 2025	Mar 16, 2026	-$0.09	-$0.22	-138.02%(-$0.13)
Q3 2025	Nov 6, 2025	-$0.04	-$0.09	-114.95%(-$0.05)
Q2 2025	Aug 7, 2025	-$0.06	$0.00	+100.00%(+$0.06)

CTMX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.40

4.36

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CTMXCytomX Therapeutics, Inc.	D	F	D	27.1x	-87.0%	—	—	$2.28
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About CytomX Therapeutics, Inc.

CytomX Therapeutics is a clinical-stage oncology company developing probody therapeutics—masked, conditionally activated biologics designed to target the tumor microenvironment. The company's proprietary technology platform creates cancer immunotherapies that activate specifically in tumors while remaining inactive in healthy tissues, enhancing efficacy and reducing potential side effects.